PharmaTwoB was founded by a group of highly experienced professionals from the Israeli pharmaceutical industry, with strong track record in drug delivery, chemistry, finance and strategic planning. The company’s management and staff are highly skilled scientists with many years of experience in research and development of drugs, pharmaceutical development and clinical trials.
Sheila Oren, MD, CEO
Sheila Oren received her MD degree from the Sackler School of Medicine, Tel Aviv University and an MBA from the Interdisciplinary Center, Herzliya. Israel. She was Chief Medical Officer at NeuroDerm, a clinical-stage pharmaceutical company developing drug-device combination treatments for CNS disorders (since 2008), where she was responsible for Product Strategy and directing the full range of clinical development and regulatory matters. Dr. Oren participated actively in the IPO of NeuroDerm when it went public on Nasdaq in November 2014. NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation (MTPC) for US$1.1 Billion in Cash in October 2017. Her prior experience (16 years with Teva Pharmaceutical Industries), covered the clinical development and medico-marketing plans and executions for new CNS drugs in the USA and Europe. Specifically, she had a major role in the development, approval, and launch of rasagiline (Azilect). Her work involved leading the global clinical trials of rasagiline for Parkinson's disease as well as guiding product information, medical training, and other medico-marketing tasks. She was key in the design the rasagiline neuroprotection study for Parkinson’s disease (the ADAGIO delayed-start study), the report of which was published in the New England Journal of Medicine in 2009.
Irit Zalayet, CFO
Ms. Irit Zalayet CPA serves as Pharma Two B’s CFO as of September 2010. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar- Ilan University. Ms. Zalayet also serves as the CFO of a related group party Stem Cell Medicine.
Hadas Friedman, VP QA, RA & Clinical Affairs
Ms. Friedman serves as Pharma Two B’s VP QA, RA and Clinical Affairs since 2013. Prior to this Ms. Friedman served as the VP QA, RA and Clinical Affairs at Intec Pharma from 2004. Previous companies include Procognia and Rafa Laboratories. Hadas has completed a Bachelors of Science and a Masters of Science at the Bar-Ilan University.